208 related articles for article (PubMed ID: 8878617)
1. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
3. Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.
Goldstein EJ; Citron DM; Vreni Merriam C; Tyrrell K; Warren Y
Antimicrob Agents Chemother; 1999 Nov; 43(11):2726-30. PubMed ID: 10543754
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Aldridge KE; Ashcraft D; Bowman KA
Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
Liebetrau A; Rodloff AC; Behra-Miellet J; Dubreuil L
Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
10. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
Ednie LM; Credito KL; Khantipong M; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
[TBL] [Abstract][Full Text] [Related]
11. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
Hecht DW; Osmolski JR
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of DU-6859a against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
[TBL] [Abstract][Full Text] [Related]
15. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
16. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
Kronvall G; Holst E
Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
[TBL] [Abstract][Full Text] [Related]
17. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of faropenem against 579 strains of anaerobic bacteria.
Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM
Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
20. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
Goldstein EJ
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
